The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
C-Type Lectin-Like Molecule-1
Abstract
Acute myeloid leukemia (AML) has a poor prognosis due to treatment-resistant relapses. A humanized anti-CD33 antibody (Mylotarg) showed a limited response rate in relapsed AML. To discover novel AML antibody targets, we selected a panel of single chain Fv fragments using phage display technology combined with flow cytometry on AML tumor samples. One selected single chain Fv fragment broadly reacted with AML samples and with myeloid cell lineages within peripheral blood. Expression cloning identified the antigen recognized as C-type lectin-like molecule-1 (CLL-1), a previously undescribed transmembrane glycoprotein. CLL-1 expression was analyzed with a human anti-CLL-1 antibody that was generated from the single chain Fv fragment. CLL-1 is restricted to the hematopoietic lineage, in particular to myeloid cells present in peripheral blood and bone marrow. CLL-1 is absent on uncommitted CD34+/CD38− or CD34+/CD33− stem cells and present on subsets of CD34+/CD38+ or CD34+/CD33+ progenitor cells. CLL-1 is not expressed in any other tissue. In contrast, analysis of primary AMLs demonstrated CLL-1 expression in 92% (68 of 74) of the samples. As an AML marker, CLL-1 was able to complement CD33, because 67% (8 of 12) of the CD33− AMLs expressed CLL-1. CLL-1 showed variable expression (10–60%) in CD34+ cells in chronic myelogenous leukemia and myelodysplastic syndrome but was absent in 12 of 13 cases of acute lymphoblastic leukemia. The AML reactivity combined with the restricted expression on normal cells identifies CLL-1 as a novel potential target for AML treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Kruif, J., Boel, E., & Logtenberg, T. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0204 · Cited by 173 · cited 1×
“antibody phage display library described previously (10) that was rescued”
BackgroundSelf-citation
Cited by
Selecting and screening recombinant antibody libraries
Hoogenboom, H. R. (2005) · Nature Biotechnology · doi:10.1038/nbt1126 · Cited by 973
Signaling by Myeloid C-Type Lectin Receptors in Immunity and Homeostasis
Sancho, D., & Reis e Sousa, C. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101352 · Cited by 520
van Rhenen, A., van Dongen, G. A. M. S., Kelder, A., Rombouts, E. J., Feller, N., Moshaver, B., Walsum, M. S.-V., Zweegman, S., Ossenkoppele, G. J., & Jan Schuurhuis, G. (2007) · Blood · doi:10.1182/blood-2007-03-083048 · Cited by 439
Self-citationCAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 396
van Rhenen, A., Feller, N., Kelder, A., Westra, A. H., Rombouts, E., Zweegman, S., van der Pol, M. A., Waisfisz, Q., Ossenkoppele, G. J., & Schuurhuis, G. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0468 · Cited by 375
Self-citation
Metadata
- Authors
- Bakker, A. B. H., van den Oudenrijn, S., Bakker, A. Q., Feller, N., van Meijer, M., Bia, J. A., Jongeneelen, M. A. C., Visser, T. J., Bijl, N., Geuijen, C. A. W., Marissen, W. E., Radosevic, K., Throsby, M., Schuurhuis, G. J., Ossenkoppele, G. J., de Kruif, J., Goudsmit, J., & Kruisbeek, A. M.
- Venue
- Cancer Research
- Published
- 2004-11-15
- Volume
- 64
- Issue
- 22
- Pages
- 8443-8450
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2113753666
- Cited by
- 247
- References
- 1
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: C-Type Lectin-Like Molecule-1. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-1659
- The paper
- Bakker, A. B. H., van den Oudenrijn, S., Bakker, A. Q., Feller, N., van Meijer, M., Bia, J. A., Jongeneelen, M. A. C., Visser, T. J., Bijl, N., Geuijen, C. A. W., Marissen, W. E., Radosevic, K., Throsby, M., Schuurhuis, G. J., Ossenkoppele, G. J., de Kruif, J., Goudsmit, J., & Kruisbeek, A. M. (2004). C-Type Lectin-Like Molecule-1. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-1659
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.